Givosiran

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis.

Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis.

Journal: Cureus

Published: March 02, 2026

Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases.

Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases.

Journal: Orphanet journal of rare diseases

Published: January 30, 2026

A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.

A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.

Journal: Molecular therapy. Nucleic acids

Published: December 19, 2025

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Journal: Nucleic acid therapeutics

Published: November 22, 2025

Acute intermittent porphyria: When diagnostic errance jeopardizes patient health

Acute intermittent porphyria: When diagnostic errance jeopardizes patient health

Journal: La Revue de medecine interne

Published: November 07, 2025

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Journal: Frontiers in pharmacology

Published: October 07, 2025

Neurovisceral Syndrome in a Patient with Monoclonal Gammopathy of Undetermined Significance: A Confirmed Case of Variegate Porphyria.

Neurovisceral Syndrome in a Patient with Monoclonal Gammopathy of Undetermined Significance: A Confirmed Case of Variegate Porphyria.

Journal: Cureus

Published: September 19, 2025

Identification of oligonucleotide drug impurities using heart-cutting two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS).

Identification of oligonucleotide drug impurities using heart-cutting two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS).

Journal: Analytica chimica acta

Published: May 25, 2025

Advances in siRNA-Loaded Nanocarriers: Harnessing Cutting-Edge Technologies for Precision Cancer Treatment.

Advances in siRNA-Loaded Nanocarriers: Harnessing Cutting-Edge Technologies for Precision Cancer Treatment.

Journal: Current pharmaceutical design

Published: April 27, 2025

Acute hepatic porphyrias.

Acute hepatic porphyrias.

Journal: Porto biomedical journal

Published: April 01, 2025

The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs.

The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: February 20, 2025

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Journal: Molecular therapy. Nucleic acids

Published: February 03, 2025

Showing 1-12 of 124

Last Updated: 06/30/2026